Last 18 quarters of trend data · Technology · Software - Infrastructure
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Core Scientific, Inc.'s quarterly P/E stands at 5.4x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -25.22 | 5.43 | — | — | 1.45 | — | — | — | 1.18 | — | — | — | — |
| — | — | — | — | +22.7% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 21.86 | 14.53 | 17.62 | 17.26 | 8.27 | 11.33 | 9.09 | 4.74 | 1.39 | — | — | — | — |
| — | +28.2% | +93.7% | +264.3% | +492.9% | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 71.39 | — | — | — | — | — | 21.02 | 4.58 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 6.26 | — | — | — | — | — | 116.74 | 1.73 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Core Scientific, Inc.'s operating margin was 16.3% in Q4 2025, up 97.0 pp QoQ and up 58.2 pp YoY. The trailing four-quarter average of -37.8% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 421.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 11.9% | 26.2% | 4.7% | 6.4% | 10.3% | 5.0% | -0.2% | 27.5% | 43.3% | 27.7% | 13.7% | 29.1% | 26.3% |
| — | +421.8% | +2945.8% | -76.8% | -76.2% | -81.9% | -101.2% | -5.5% | +64.4% | +171.1% | +182.0% | +275.5% | -27.6% | |
| Operating Margin | -45.4% | 16.3% | -80.7% | -33.4% | -53.6% | -41.9% | -43.2% | 4.7% | 30.8% | 2.8% | -10.7% | 7.5% | 6.3% |
| — | +138.9% | -86.7% | -816.9% | -273.9% | -1612.0% | -305.2% | -37.5% | +388.9% | +100.5% | +95.7% | +101.2% | +145.4% | |
| Net Margin | -90.5% | 268.5% | -180.8% | -1191.4% | 730.2% | -279.7% | -477.4% | -570.4% | 117.5% | -137.9% | -36.4% | -7.3% | -0.3% |
| — | +196.0% | +62.1% | -108.9% | +521.4% | -102.9% | -1210.1% | -7718.0% | +36640.2% | +61.6% | +86.4% | +98.5% | +99.9% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -14.6% | 9.2% | -6.9% | -52.0% | 36.0% | -21.1% | -54.1% | -102.2% | 27.6% | -27.6% | -5.7% | -1.2% | -0.0% |
| — | +143.8% | +87.3% | +49.1% | +30.5% | +23.7% | -857.2% | -8235.9% | +55880.4% | +29.8% | +78.9% | +96.6% | +99.7% | |
| ROIC | — | — | — | — | -10.2% | — | — | — | 18.1% | 1.0% | -2.4% | 33.1% | 11.9% |
| — | — | — | — | -156.0% | — | — | — | +51.6% | +100.7% | +90.1% | +178.5% | +1390.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Core Scientific, Inc.'s Debt/EBITDA ratio is 56.2x — elevated, raising questions about debt serviceability. The current ratio has weakened 82.9% YoY to 1.15x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | 56.24 | — | — | — | — | — | 16.32 | 7.72 | 24.82 | 69.62 | 0.97 | 33.67 |
| — | — | — | — | — | — | — | +1589.3% | -77.1% | — | — | — | -58.5% | |
| Current Ratio | 1.15 | 1.15 | 1.58 | 1.79 | 4.26 | 6.72 | 3.63 | 1.58 | 1.04 | 0.20 | 0.43 | 0.59 | 0.33 |
| — | -82.9% | -56.4% | +13.4% | +310.8% | +3282.1% | +742.8% | +165.4% | +212.9% | -56.4% | +160.1% | -40.1% | -83.0% | |
| Quick Ratio | 1.15 | 1.15 | 1.58 | 1.79 | 4.26 | 6.72 | 3.63 | 1.58 | 1.04 | 0.20 | 0.43 | 0.59 | 0.33 |
| — | -82.9% | -56.4% | +13.4% | +310.8% | +3282.1% | +742.8% | +165.4% | +212.9% | -56.4% | +160.1% | -40.1% | -83.0% | |
| Interest Coverage | -44.16 | 14.20 | — | — | — | -35.02 | -5.83 | 0.45 | 3.92 | 0.05 | -5.48 | — | 48.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 18 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CORZ stock.
Core Scientific, Inc.'s current P/E is -25.2x. The average P/E over the last 2 quarters is 3.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Core Scientific, Inc.'s current operating margin is -45.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Core Scientific, Inc.'s business trajectory between earnings reports.